DOCSLIB.ORG

Meeting Program

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Meeting Program BOARD OF DIRECTORS Sharon Walsh, PhD, President A. Thomas McLellan, PhD Stephen T. Higgins, PhD, Past-President Geoffrey K. Mumford, PhD Linda J. Porrino, PhD, President-Elect Michael A. Nader, PhD Stephen G. Holtzman, PhD, Treasurer Edward V. Nunes, MD Patrick M. Beardsley, PhD Alison Oliveto-Beaudoin, PhD Steven R. Childers, PhD Richard A. Rawson, PhD Theodore J. Cicero, PhD Maxine L. Stitzer, PhD Richard De La Garza, II, PhD Eric C. Strain, MD Toby K. Eisenstein, PhD Dace S. Svikis, PhD David A. Fiellin, MD EXECUTIVE OFFICER Martin W. Adler, PhD SCIENTIFIC PROGRAM COMMITTEE Sari Izenwasser, PhD, Chair Martin W. Adler, PhD, ex officio Ellen B. Geller, MA, ex officio Alan Budney, PhD Sandra Comer, PhD Mark Greenwald, PhD Kathleen Kantak, PhD Michelle Lofwall, MD Lance McMahon, PhD Dace Svikis, PhD Jennifer Tidey, PhD Ellen Unterwald, PhD Elise Weerts, PhD Friedbert Weiss, PhD Saturday, June 20, 2009 PRE-MEETING SATELLITES The International Study Group Investigating Bonanza A Drugs as Reinforcers (ISGIDAR) Chaired by Elise Weerts 9 th Annual Meeting Center for Substance Abuse Bonanza B and Treatment (CSAT) Southern Pacific B/F Chaired by Cathy Crowley The 14th Annual NIDA International Forum on Ponderosa B and Building International Research on Drug Abuse: Pavilion C/E Progress through Collaboration Chaired by Steven Gust Treating Addiction during Pregnancy: Exploring Multinational Bonanza A Perspectives to Build a Treatment Approach Consensus 8:00 - 10:00 PM Chaired by Hendree Jones CPDD REGISTRATION Ponderosa A Saturday, June 20 1:30 PM - 5:00 PM (Pool Area) 7:00 PM - 7:30 PM Sunday, June 21 8:00 AM - 12:00 PM 1:30 PM - 5:00 PM Monday, June 22 8:00 AM - 12:00 PM 1:30 PM - 5:00 PM Tuesday, June 23 8:00 AM - 1:00 PM Wednesday, June 24 8:00 AM - 12:00 PM 1:30 PM - 5:00 PM Thursday, June 25 8:00 AM - 1:00 PM OPENING RECEPTION 7:00 - 9:00 PM (Cash Bar) Pool Area Sunday, June 21, 2009 CSAT Travel Awards Breakfast Poolside Terrace (By Invitation Only) 7:00 - 8:00 AM Plenary Session Rose Ballroom A 8:30 - 11:00 AM 8:30 Welcome, CPDD President Sharon L. Walsh 8:45 Report from the National Institute on Drug Abuse Nora Volkow, NIDA 9:15 Presentation of the CPDD/NIDA Media Award to Nancy Campbell Introduction by Marc J. Kaufman 9:25 Presentation of the Joseph Cochin Young Investigator Award to Laura Bohn Introduction by Linda Dykstra 9:30 Presentation of the Mentorship Award to George Bigelow Introduction by Stephen Higgins 9:35 Presentation of the Nathan B. Eddy Award to Robert L. Balster Introduction by Louis Harris 9:40 Nathan B. Eddy Award Lecture Robert L. Balster EARLY CAREER INVESTIGATOR AWARDS LUNCHEON Poolside Terrace (By Invitation Only) 11:30 AM - 1:00 PM Presidential Symposium Rose Ballroom A 1:00 - 3:00 PM OPIOID RECEPTORS FROM THE CUTTING EDGE TO THE CLINIC: KNOCKOUTS, CROSSTALK AND BEHAVIOR Chair: Sharon L. Walsh 1:00 Our shifting view of the nature of the opioid receptors Christopher Evans, University of California, Los Angeles, Los Angeles, CA 1:20 Cellular mechanisms of opioid receptor regulation Mark Van Zastrow, University of California, San Francisco, CA 1:40 Novel mouse model of human OPRM1 polymorphism (A118G) Julie Blendy, University of Pennsylvania, Philadelphia, PA 2:00 Involvement of the endogenous opioid system in nicotine reward Rafael Maldonado, Universitat Pompeu Fabra, Barcelona, Spain 2:20 Discussant Nora Volkow, Director of NIDA BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS 1 Sunday, June 21, 2009 Symposium I Ponderosa B 3:15 - 5:15 PM HOW DOES STRESS CONTRIBUTE TO ADDICTION VULNERABILITY? STUDIES FROM ADOLESCENT AND ADULT SAMPLES Chairs: Rajita Sinha and Kathleen T. Brady 3:15 Racial differences in stress, emotional regulation and DSM-IV substance abuse and dependence in young, low-income women Helen Wu, University of Texas Medical School-Houston, Galveston, TX 3:40 Hypothalamic-pituitary-adrenal axis and substance use among adolescents: The TRAILS study Anja Huizink, Erasmus Medical Center, Rotterdam, CB Rotterdam, Netherlands 4:05 Stress response and risk for substance use in prenatally cocaine-exposed and non-exposed adolescents Tara Chaplin, Linda Mayes, Yale University School of Medicine, New Haven, CT 4:30 Altered nucleus accumbens activity in individuals with high childhood trauma is predictive of addictive behaviors Rajita Sinha, Zhiru Jia, Yale Stress Center, Yale University School of Medicine, New Haven, CT 4:55 Discussant Kathleen T. Brady, Medical University of South Carolina, Charleston, SC Symposium II Bonanza 3:15 - 5:15 PM VIRTUAL MODELING:A NEW FRONTIER FOR INVESTIGATING DRUG-RECEPTOR INTERACTIONS Chair: Christopher K. Surratt 3:15 Uptake inhibitor interactions in the primary and “staging area” substrate pockets of the plasma membrane monoamine transporters Christopher K. Surratt, Duquesne University, Mylan School of Pharmacy, Pittsburgh, PA 3:40 Ligand-receptor docking of epibatidine analogs to a nicotinic acetylcholine receptor model S. Wayne Mascarella, Research Triangle Institute, Research Triangle Park, NC 4:05 Understanding sigma receptor ligand interactions Christopher McCurdy, University of Mississippi School of Pharmacy, University, MS 4:30 A structural model of salvinorin A recognition at the kappa opioid receptor David M. Ferguson, University of Minnesota, Minneapolis, MN 4:55 Discussant F. Ivy Carroll, Research Triangle Institute, Research Triangle Park, NC BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS 2 Sunday, June 21, 2009 Oral Communications 1 Rose Ballroom A 3:15 - 5:15 PM A FULL HOUSE OF NOVEL TREATMENTS Chairs: Susan C. Sonne and Kevin Gray 3:15 Extended-release naltrexone for treatment of alcohol dependence in primary care J. D. Lee, E. Grossman, D. DiRocco, J. Rotrosen, D. Stevens, M. Gourevitch, Medicine, NYU School of Medicine, New York, NY 3:30 The use of acamprosate vs placebo in alcoholics with comorbid anxiety or depression S. C. Sonne1, J. S. Potter2, R. N. Rosenthal3, C. Tyson1, 1Medical University of South Carolina, Charleston, SC, 2McLean Hospital, Belmont, MA, 3Columbia University, New York, NY 3:45 A randomized placebo-controlled trial of sertraline and sertraline plus gabapentin in depressed, recently abstinent cocaine-dependent patients M. J. Mancino, Z. Feldman, M. Chopra, C. S. Cargile, A. Oliveto, Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR 4:00 Atomoxetine in marijuana-dependent adults with ADHD A. McRae-Clark1, R. E. Carter2, T. K. Killeen1, M. J. Carpenter1, K. T. Brady1, 1Psychiatry, Medical University of South Carolina, Charleston, SC, 2Biometry, Medical University of South Carolina, Charleston, SC 4:15 Bupropion SR and contingency management in adolescent smokers: Main findings K. M. Gray1, M. J. Carpenter1, N. L. Baker1, E. M. Klintworth1, A. S. Leinbach1, H. P. Upadhyaya1,2, 1Medical University of South Carolina, Charleston, SC, 2Eli Lilly and Company, Indianapolis, IN 4:30 Dextroamphetamine as a treatment for methamphetamine dependence G. P. Galloway, L. Fiske, J. D. Siegrist, M. J. Baggott, K. Flower, R. Buscemi, D. Polcin, J. Mendelson, Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA 4:45 Long-acting vs. oral naltrexone for preventing heroin addiction relapse E. Krupitsky1, E. Zvartau1, E. Verbitskaya1, V.Egorova1, D. Masalov1, M. Tsoi1, A. Burakov1, N. Bushara1, T. Romanova1, T. Slavina1, A. Tyurina1, V.Palatkin1, G. E. Woody2, 1Addictions, Pavlov State Medical University, St. Petersburg, Russia, 2Psychiatry, University of Pennsylvania, Philadelphia, PA Oral Communications 2 Rose Ballroom B 3:15 - 5:15 PM AGING AND DEATH:THE DECK IS STACKED Chairs: Stefan Kertesz and Howard Chilcoat 3:15 Prescription drug use among baby boomers: Insights from clinician interviews C. L. Striley, K. S. Leung, V.Satyanarayana, A. Ben Abdallah, L. B. Cottler, Psychiatry, Washington University School of Medicine, St. Louis, MO 3:30 Trajectories of illicit drug use among adults in the general population (the CARDIA study) S. Kertesz1,2, M. Pletcher3, B. Jones4, J. Tucker2, Y. Khodneva2, 1Birmingham VAMC, Birmingham, AL, 2University of Alabama, Birmingham, AL, 3University of California, San Francisco, CA, 4Carnegie-Mellon University, Pittsburgh, PA 3 Sunday, June 21, 2009 3:45 Testing pathways between alcohol and opioid dependence H. Chilcoat1,3, N. Dasgupta2,1, S. S. Martins3, 1Worldwide Epidemiology, GlaxoSmithKline, Research Triangle Park, NC, 2Epidemiology, University of North Carolina, Chapel Hill, NC, 3Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 4:00 Late injection drug use initiators: Epidemiological trends and risk factors A. Kral1,2, L. Wenger1, L. Carpenter1, P. Bourgois3, M. Iguchi5,4, R. Bluthenthal4,6, 1RTI International, San Francisco, CA, 2University of California, San Francisco, CA, 3University of Pennsylvania, Philadelphia, PA, 4RAND, Santa Monica, CA, 5University of California, Los Angeles, CA, 6California State University, Dominguez Hills, Los Angeles, CA 4:15 Persistence of cocaine use once it starts: Initial findings from epidemiological research E. Meyer, J. Anthony, Epidemiology, Michigan State University, East Lansing, MI 4:30 Age effects on heroin and prescription opioid abuse among enrollees into methadone maintenance treatment C. Cleland1, A. Rosenblum1, C. Fong1, M. Parrino2, S. Magura3,1, 1National Development and Research Institutes, Inc., New York, NY, 2American Association for the Treatment of Opioid Dependence, New York, NY, 3Western Michigan University, Kalamazoo, MI 4:45 Medical examiner methadone-related
Load more

Recommended publications
  • The Pharmacologist 2 0 0 6 December
    Vol. 48 Number 4 The Pharmacologist 2 0 0 6 December 2006 YEAR IN REVIEW The Presidential Torch is passed from James E. Experimental Biology 2006 in San Francisco Barrett to Elaine Sanders-Bush ASPET Members attend the 15th World Congress in China Young Scientists at EB 2006 ASPET Awards Winners at EB 2006 Inside this Issue: ASPET Election Online EB ’07 Program Grid Neuropharmacology Division Mixer at SFN 2006 New England Chapter Meeting Summary SEPS Meeting Summary and Abstracts MAPS Meeting Summary and Abstracts Call for Late-Breaking Abstracts for EB‘07 A Publication of the American Society for 121 Pharmacology and Experimental Therapeutics - ASPET Volume 48 Number 4, 2006 The Pharmacologist is published and distributed by the American Society for Pharmacology and Experimental Therapeutics. The Editor PHARMACOLOGIST Suzie Thompson EDITORIAL ADVISORY BOARD Bryan F. Cox, Ph.D. News Ronald N. Hines, Ph.D. Terrence J. Monks, Ph.D. 2006 Year in Review page 123 COUNCIL . President Contributors for 2006 . page 124 Elaine Sanders-Bush, Ph.D. Election 2007 . President-Elect page 126 Kenneth P. Minneman, Ph.D. EB 2007 Program Grid . page 130 Past President James E. Barrett, Ph.D. Features Secretary/Treasurer Lynn Wecker, Ph.D. Secretary/Treasurer-Elect Journals . Annette E. Fleckenstein, Ph.D. page 132 Past Secretary/Treasurer Public Affairs & Government Relations . page 134 Patricia K. Sonsalla, Ph.D. Division News Councilors Bryan F. Cox, Ph.D. Division for Neuropharmacology . page 136 Ronald N. Hines, Ph.D. Centennial Update . Terrence J. Monks, Ph.D. page 137 Chair, Board of Publications Trustees Members in the News .
    [Show full text]
  • The Cross-Talk of HIV-1 Tat and Methamphetamine in HIV-Associated Neurocognitive Disorders
    REVIEW published: 23 October 2015 doi: 10.3389/fmicb.2015.01164 The cross-talk of HIV-1 Tat and methamphetamine in HIV-associated neurocognitive disorders Sonia Mediouni 1, Maria Cecilia Garibaldi Marcondes 2, Courtney Miller 3,4, Jay P. McLaughlin 5 and Susana T. Valente 1* 1 Department of Infectious Diseases, The Scripps Research Institute, Jupiter, FL, USA, 2 Department of Molecular and Cellular Neurosciences, The Scripps Research Institute, La Jolla, CA, USA, 3 Department of Metabolism and Aging, The Scripps Research Institute, Jupiter, FL, USA, 4 Department of Neuroscience, The Scripps Research Institute, Jupiter, FL, USA, 5 Department of Pharmacodynamics, University of Florida, Gainesville, FL, USA Antiretroviral therapy has dramatically improved the lives of human immunodeficiency virus 1 (HIV-1) infected individuals. Nonetheless, HIV-associated neurocognitive disorders (HAND), which range from undetectable neurocognitive impairments to severe dementia, still affect approximately 50% of the infected population, hampering their quality of life. The persistence of HAND is promoted by several factors, including longer life expectancies, Edited by: the residual levels of virus in the central nervous system (CNS) and the continued Venkata S. R. Atluri, presence of HIV-1 regulatory proteins such as the transactivator of transcription (Tat) Florida International University, USA Reviewed by: in the brain. Tat is a secreted viral protein that crosses the blood–brain barrier into the Masanori Baba, CNS, where it has the ability to directly act on neurons and non-neuronal cells alike. Kagoshima University, Japan These actions result in the release of soluble factors involved in inflammation, oxidative Shilpa J. Buch, University of Nebraska Medical stress and excitotoxicity, ultimately resulting in neuronal damage.
    [Show full text]
  • A Role for Sigma Receptors in Stimulant Self Administration and Addiction
    Pharmaceuticals 2011, 4, 880-914; doi:10.3390/ph4060880 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review A Role for Sigma Receptors in Stimulant Self Administration and Addiction Jonathan L. Katz *, Tsung-Ping Su, Takato Hiranita, Teruo Hayashi, Gianluigi Tanda, Theresa Kopajtic and Shang-Yi Tsai Psychobiology and Cellular Pathobiology Sections, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, MD, 21224, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]. Received: 16 May 2011; in revised form: 11 June 2011 / Accepted: 13 June 2011 / Published: 17 June 2011 Abstract: Sigma1 receptors (σ1Rs) represent a structurally unique class of intracellular proteins that function as chaperones. σ1Rs translocate from the mitochondria-associated membrane to the cell nucleus or cell membrane, and through protein-protein interactions influence several targets, including ion channels, G-protein-coupled receptors, lipids, and other signaling proteins. Several studies have demonstrated that σR antagonists block stimulant-induced behavioral effects, including ambulatory activity, sensitization, and acute toxicities. Curiously, the effects of stimulants have been blocked by σR antagonists tested under place-conditioning but not self-administration procedures, indicating fundamental differences in the mechanisms underlying these two effects. The self administration of σR agonists has been found in subjects previously trained to self administer cocaine. The reinforcing effects of the σR agonists were blocked by σR antagonists. Additionally, σR agonists were found to increase dopamine concentrations in the nucleus accumbens shell, a brain region considered important for the reinforcing effects of abused drugs.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Neuropharmacology and Toxicology of Novel Amphetamine-Type Stimulants
    Neuropharmacology and toxicology of novel amphetamine-type stimulants Bjørnar den Hollander Institute of Biomedicine, Pharmacology University of Helsinki Academic Dissertation To be presented, with the permission of the Medical Faculty of the University of Helsinki, for public examination in lecture hall 2, Biomedicum Helsinki 1, Haartmaninkatu 8, on January 16th 2015 at 10 am. Helsinki 2015 Supervisors Thesis committee Esa R. Korpi, MD, PhD Eero Castrén, MD, PhD Institute of Biomedicine, Pharmacology Neuroscience Center Faculty of Medicine University of Helsinki P.O. Box 63 (Haartmaninkatu 8) P.O. Box 56 (Viikinkaari 4) 00014 University of Helsinki, Finland 00014 University of Helsinki, Finland Esko Kankuri, MD, PhD Sari Lauri, PhD Institute of Biomedicine, Pharmacology Neuroscience Center and Faculty of Medicine Department of Biosciences/ Physiology P.O. Box 63 (Haartmaninkatu 8) University of Helsinki 00014 University of Helsinki, Finland P.O.Box 65 (Viikinkaari 1) 00014 University of Helsinki, Finland Reviewers Dissertation opponent Atso Raasmaja, Professor, PhD Prof David Nutt DM FRCP FRCPsych Division of Pharmacology and FMedSci Pharmacotherapy Edmond J. Safra Chair of Faculty of Pharmacy Neuropsychopharmacology P. O. Box 56 (Viikinkaari 5E) Division of Brain Sciences 00014 University of Helsinki, Finland Dept of Medicine Imperial College London Petri J. Vainio, MD, PhD Burlington Danes Building Pharmacology, Drug Development and Hammersmith Hospital Therapeutics Du Cane Road Institute of Biomedicine London W12 0NN, United Kingdom Faculty of Medicine Kiinamyllynkatu 10 C 20014 University of Turku, Finland The cover layout is done by Anita Tienhaara. The cover photo is by Edd Westmacott and shows a close-up of ecstasy tablets, photographed in Amsterdam in 2004.
    [Show full text]
  • Comprehensive Review on the Interaction Between Natural Compounds and Brain Receptors: Benefits and Toxicity
    European Journal of Medicinal Chemistry 174 (2019) 87e115 Contents lists available at ScienceDirect European Journal of Medicinal Chemistry journal homepage: http://www.elsevier.com/locate/ejmech Review article Comprehensive review on the interaction between natural compounds and brain receptors: Benefits and toxicity * Ana R. Silva a, Clara Grosso b, , Cristina Delerue-Matos b,Joao~ M. Rocha a, c a Centre of Molecular and Environmental Biology (CBMA), Department of Biology (DB), University of Minho (UM), Campus Gualtar, P-4710-057, Braga, Portugal b REQUIMTE/LAQV, Instituto Superior de Engenharia do Instituto Politecnico do Porto, Rua Dr. Antonio Bernardino de Almeida, 431, P-4249-015, Porto, Portugal c REQUIMTE/LAQV, Grupo de investigaçao~ de Química Organica^ Aplicada (QUINOA), Laboratorio de polifenois alimentares, Departamento de Química e Bioquímica (DQB), Faculdade de Ci^encias da Universidade do Porto (FCUP), Rua do Campo Alegre, s/n, P-4169-007, Porto, Portugal article info abstract Article history: Given their therapeutic activity, natural products have been used in traditional medicines throughout the Received 6 December 2018 centuries. The growing interest of the scientific community in phytopharmaceuticals, and more recently Received in revised form in marine products, has resulted in a significant number of research efforts towards understanding their 10 April 2019 effect in the treatment of neurodegenerative diseases, such as Alzheimer's (AD), Parkinson (PD) and Accepted 11 April 2019 Huntington (HD). Several studies have shown that many of the primary and secondary metabolites of Available online 17 April 2019 plants, marine organisms and others, have high affinities for various brain receptors and may play a crucial role in the treatment of diseases affecting the central nervous system (CNS) in mammalians.
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]
  • Lobelane Analogs with Various Methylene Linker Lengths and Acyclic Lobelane Analogs As Potential Pharmacotherapies to Treat Methamphetamine Abuse
    University of Kentucky UKnowledge Theses and Dissertations--Pharmacy College of Pharmacy 2014 LOBELANE ANALOGS WITH VARIOUS METHYLENE LINKER LENGTHS AND ACYCLIC LOBELANE ANALOGS AS POTENTIAL PHARMACOTHERAPIES TO TREAT METHAMPHETAMINE ABUSE Zheng Cao University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Cao, Zheng, "LOBELANE ANALOGS WITH VARIOUS METHYLENE LINKER LENGTHS AND ACYCLIC LOBELANE ANALOGS AS POTENTIAL PHARMACOTHERAPIES TO TREAT METHAMPHETAMINE ABUSE" (2014). Theses and Dissertations--Pharmacy. 32. https://uknowledge.uky.edu/pharmacy_etds/32 This Doctoral Dissertation is brought to you for free and open access by the College of Pharmacy at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Pharmacy by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File. I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known.
    [Show full text]
  • Implications of Dopamine D3 Receptor for Glaucoma: In-Silico and In-Vivo Studies
    International PhD Program in Neuropharmacology XXVI Cycle Implications of dopamine D3 receptor for glaucoma: in-silico and in-vivo studies PhD thesis Chiara Bianca Maria Platania Coordinator: Prof. Salvatore Salomone Tutor: Prof. Claudio Bucolo Department of Clinical and Molecular Biomedicine Section of Pharmacology and Biochemistry. University of Catania - Medical School December 2013 Copyright ©: Chiara B. M. Platania - December 2013 2 TABLE OF CONTENTS ACKNOWLEDGEMENTS............................................................................ 4 LIST OF ABBREVIATIONS ........................................................................ 5 ABSTRACT ................................................................................................... 7 GLAUCOMA ................................................................................................ 9 Aqueous humor dynamics .................................................................. 10 Pharmacological treatments of glaucoma............................................ 12 Pharmacological perspectives in treatment of glaucoma ..................... 14 Animal models of glaucoma ............................................................... 18 G PROTEIN COUPLED RECEPTORS ....................................................... 21 GPCRs functions and structure ........................................................... 22 Molecular modeling of GPCRs ........................................................... 25 D2-like receptors ...............................................................................
    [Show full text]
  • Activation of D1R/PKA/Mtor Signaling Cascade in Medial
    www.nature.com/scientificreports OPEN Activation of D1R/PKA/mTOR signaling cascade in medial prefrontal cortex underlying the Received: 17 November 2016 Accepted: 3 May 2017 antidepressant effects ofl -SPD Published: xx xx xxxx Bing Zhang1,2,3, Fei Guo1, Yuqin Ma1,2, Yingcai Song3, Rong Lin3, Fu-Yi Shen3, Guo-Zhang Jin1, Yang Li 1 & Zhi-Qiang Liu3 Major depressive disorder (MDD) is a common neuropsychiatric disorder characterized by diverse symptoms. Although several antidepressants can influence dopamine system in the medial prefrontal cortex (mPFC), but the role of D1R or D2R subtypes of dopamine receptor during anti-depression process is still vague in PFC region. To address this question, we investigate the antidepressant effect of levo-stepholidine (l-SPD), an antipsychotic medication with unique pharmacological profile of D1R agonism and D2R antagonism, and clarified its molecular mechanisms in the mPFC. Our results showed that l-SPD exerted antidepressant-like effects on the Sprague-Dawley rat CMS model of depression. Mechanism studies revealed that l-SPD worked as a specific D1R agonist, rather than D2 antagonist, to activate downstream signaling of PKA/mTOR pathway, which resulted in increasing synaptogenesis-related proteins, such as PSD 95 and synapsin I. In addition, l-SPD triggered long- term synaptic potentiation (LTP) in the mPFC, which was blocked by the inhibition of D1R, PKA, and mTOR, supporting that selective activation of D1R enhanced excitatory synaptic transduction in PFC. Our findings suggest a critical role of D1R/PKA/mTOR signaling cascade in the mPFC during thel -SPD mediated antidepressant process, which may also provide new insights into the role of mesocortical dopaminergic system in antidepressant effects.
    [Show full text]
  • Handbook of Schizophrenia Spectrum Disorders, Volume III
    Handbook of Schizophrenia Spectrum Disorders, Volume III Michael S. Ritsner Editor Handbook of Schizophrenia Spectrum Disorders, Volume III Therapeutic Approaches, Comorbidity, and Outcomes 123 Editor Michael S. Ritsner Technion – Israel Institute of Technology Rappaport Faculty of Medicine Haifa Israel [email protected] ISBN 978-94-007-0833-4 e-ISBN 978-94-007-0834-1 DOI 10.1007/978-94-007-0834-1 Springer Dordrecht Heidelberg London New York Library of Congress Control Number: 2011924745 © Springer Science+Business Media B.V. 2011 No part of this work may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) Foreword Schizophrenia Spectrum Disorders: Insights from Views Across 100 years Schizophrenia spectrum and related disorders such as schizoaffective and mood dis- orders, schizophreniform disorders, brief psychotic disorders, delusional and shared psychotic disorders, and personality (i.e., schizotypal, paranoid, and schizoid per- sonality) disorders are the most debilitating forms of mental illness, worldwide. There are 89,377 citations (including 10,760 reviews) related to “schizophrenia” and 2118 (including 296 reviews) related to “schizophrenia spectrum” in PubMed (accessed on August 12, 2010). The classification of these disorders, in particular, of schizophrenia, schizoaf- fective and mood disorders (referred to as functional psychoses), has been debated for decades, and its validity remains controversial.
    [Show full text]
  • Discovery of E1r: a Novel Positive Allosteric Modulator of Sigma-1 Receptor
    Edijs Vāvers DISCOVERY OF E1R: A NOVEL POSITIVE ALLOSTERIC MODULATOR OF SIGMA-1 RECEPTOR Doctoral Thesis for obtaining the degree of Doctor of Pharmacy Speciality − Pharmaceutical Pharmacology Scientific supervisor: Dr. pharm., Professor Maija Dambrova Riga, 2017 ANNOTATION Sigma-1 receptor (Sig1R) is a new drug target. Notably, the International Union of Basic and Clinical Pharmacology included Sig1R in its list of receptors only in 2013. It is believed that Sig1R ligands are potential novel drug candidates for the treatment of central and peripheral nervous system diseases. The aim of this thesis was to evaluate the pharmacological activity of novel Sig1R ligands and to search for their possible clinical applications. Methylphenylpiracetam (2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide) was synthesised in the Latvian Institute of Organic Synthesis. There are two chiral centres in the molecular structure of methylphenylpiracetam; therefore, it is possible to isolate four individual stereoisomers, which are denoted E1R, T1R, E1S and T1S. The activity of E1R was profiled using commercially available screening assays, which showed that the compound selectively modulates Sig1R activity but does not affect the other investigated neuronal receptors and ion channels. The following detailed in vitro studies, in which more selective Sig1R ligands were used, provided solid evidence that E1R is a positive allosteric modulator of Sig1R. It was found that the enantiomers with the R-configuration at the C-4 chiral centre in the 2-pyrrolidone ring (E1R and T1R) are more effective positive allosteric modulators of Sig1R than their optical antipodes. Since Sig1R agonists demonstrate neuroprotective properties and are effective in the treatment of cognitive disorders of various origins, the activity of E1R was tested in experimental models in vivo.
    [Show full text]